Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
RYE, N.Y., May 3 /PRNewswire/ -- Dr. Joan Fallon, founder and
CEO of Curemark, LLC, (www.curemark.com), a drug research and
development company focused on the treatment of neurological
diseases, presented at the Keystone Symposia meeting, Toward
Defining the Pathophysiology of Autistic Behavior, held in April in
Snowbird, Utah.
Fallon presented on "The Role of Protein Assimilation and
Utilization in Children with Autism." She discussed Curemark's
research exploring a possible link between a lack of
protein-digesting enzymes in autistic children, necessary for the
production of amino acids needed for brain function, and the
symptoms of autism.
"The Keystone Symposia meeting provided an excellent forum to
share our research with others in the scientific community who are
attempting to understand the physiological causes of autism and
working to develop possible therapies," Fallon said.
Curemark is in the midst of Phase III clinical trials for CM-AT,
its autism treatment targeted as enzyme replacement therapy. CM-AT
recently was designated as a Fast Track drug by the FDA.
Keystone Symposia on Molecular and Cellular Biology is a
non-profit organization with a 38-year history of organizing
conferences to connect the scientific community and accelerate
scientific discoveries.
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointestinal/pancreatic secretory deficiencies. The company's
initial products are based upon breakthrough observations by its
founder, Dr. Joan Fallon, which revealed a lack of protein
digestion in children with autism and ADHD. To learn more about our
innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that
involve risks and uncertainties that could cause our actual results
and experiences to differ materially from anticipated results and
expectations expressed in such forward-looking statement. These
forward-looking statements include, without limitation, statements
regarding the mechanism of action of CM-AT, its potential
advantages, its potential for use in treating autism, as well as
the timing, progress and anticipated results of the clinical
development and regulatory processes concerning CM-AT. These
statements are based on our current beliefs and expectations as to
such future outcomes, and are subject to known and unknown risks
and uncertainties that may cause actual future experience and
results to differ materially from the statements made. Factors that
might cause such a material difference include, among others, risks
that the results of clinical trials will not support our claims or
beliefs concerning the effectiveness of CM-AT, our ability to
finance our development of CM-AT, regulatory risks, and our
reliance on third party researchers and other collaborators. We
assume no obligation to update these statements, except as required
by law.
Source: Curemark LLC
CONTACT: Michelle Manoff, Rubenstein Public Relations,
212-843-8051,
mmanoff@rubensteinpr.com; Dr.
Joan Fallon, Curemark LLC, +1-914-925-3450,
joan.fallon@curemark.com
Posted: May 2010
